TY - JOUR

T1 - New drug-development paradigms? Opportunities and uncertainties with new government drug repurposing programmes

AU - Liddicoat, Johnathan

AU - Hamidzadeh , Ashleigh

AU - Liddell, Kathleen

AU - Schito, Marco

AU - Simon, David

AU - Aboy, Mateo

AU - Minssen, Timo

N1 - Liddicoat J, Hamidzadeh A, Liddell K, Schito M, Simon D, Aboy M, Minssen T. New government drug repurposing programs: Opportunities and uncertainties. Sci Transl Med. 2024 Jun 26;16(753):eadl0998. doi: 10.1126/scitranslmed.adl0998. Epub 2024 Jun 26. PMID: 38924430.

PY - 2024/6/26

Y1 - 2024/6/26

N2 - KEY MESSAGES●Governments in the US, UK and EU have recently established seven drug-repurposing programmes that aim to overcome legal and regulatory hurdles.●The programmes all operate in different ways, presenting a variety of opportunities for all organisations in drug development, including charities and academics.●Perhaps more profoundly, at least three of the programmes also constitute new models of drug development, relying less on patents and private industry and more on government involvement and clinical trials run by the public sector.●These new models could lead to relatively fast, inexpensive therapies. Yet, how effective the programmes will be and how they could be improved is uncertain, and the comparison in this paper paves the way to address these essential issues.

AB - KEY MESSAGES●Governments in the US, UK and EU have recently established seven drug-repurposing programmes that aim to overcome legal and regulatory hurdles.●The programmes all operate in different ways, presenting a variety of opportunities for all organisations in drug development, including charities and academics.●Perhaps more profoundly, at least three of the programmes also constitute new models of drug development, relying less on patents and private industry and more on government involvement and clinical trials run by the public sector.●These new models could lead to relatively fast, inexpensive therapies. Yet, how effective the programmes will be and how they could be improved is uncertain, and the comparison in this paper paves the way to address these essential issues.

KW - Faculty of Law

KW - Government Programs

KW - drug R&D

KW - new uses

KW - drug repurposing

KW - Public private partnership

KW - Emperical legal studies

UR - https://www.science.org/doi/10.1126/scitranslmed.adl0998?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed

U2 - 10.1126/scitranslmed.adl0998

DO - 10.1126/scitranslmed.adl0998

M3 - Journal article

C2 - 38924430

VL - 16

JO - Science Translational Medicine

JF - Science Translational Medicine

SN - 1946-6234

IS - 753

ER -